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Sirtuin 3 deficiency does not alter 
host defenses against bacterial and 
fungal infections
Eleonora Ciarlo  1, Tytti Heinonen1, Jérôme Lugrin  1, Hans Acha-Orbea2, Didier Le Roy1, 
Johan Auwerx3 & Thierry Roger  1
Sirtuin 3 (SIRT3) is the main mitochondrial deacetylase. SIRT3 regulates cell metabolism and redox 
homeostasis, and protects from aging and age-associated pathologies. SIRT3 may drive both oncogenic 
and tumor-suppressive effects. SIRT3 deficiency has been reported to promote chronic inflammation-
related disorders, but whether SIRT3 impacts on innate immune responses and host defenses against 
infections remains essentially unknown. This aspect is of primary importance considering the great 
interest in developing SIRT3-targeted therapies. Using SIRT3 knockout mice, we show that SIRT3 
deficiency does not affect immune cell development and microbial ligand-induced proliferation 
and cytokine production by splenocytes, macrophages and dendritic cells. Going well along with 
these observations, SIRT3 deficiency has no major impact on cytokine production, bacterial burden 
and survival of mice subjected to endotoxemia, Escherichia coli peritonitis, Klebsiella pneumoniae 
pneumonia, listeriosis and candidiasis of diverse severity. These data suggest that SIRT3 is not critical 
to fight infections and support the safety of SIRT3-directed therapies based on SIRT3 activators or 
inhibitors for treating metabolic, oncologic and neurodegenerative diseases without putting patients at 
risk of infection.
The innate immune system provides the first line of defense against microbial infections. Innate immune cells 
such as macrophages and dendritic cells (DCs) detect invading microorganisms through pattern recognition 
receptors (PRRs). The best-characterized family of PRRs is constituted by Toll-like receptors (TLRs), which medi-
ate the sensing of a broad range of microbial structures1. The interaction between PRRs and microbial ligands 
activates intracellular signaling pathways that coordinate the expression of immune-regulatory genes among 
which cytokines/chemokines, and the development of humoral and cellular responses required to neutralize or 
eliminate pathogens and restore homeostasis.
Sirtuins (SIRT1–7) belong to the NAD+-dependent class III subfamily of histone deacetylases (HDACs)2. 
Besides histones, sirtuins target thousands of non-histone proteins, among which chromatin modifiers, tran-
scription regulators, signal transduction molecules, metabolic enzymes and structural cell components3. SIRT1–7 
localize in the cytosol, nucleus and/or mitochondria, which dictates their accessibility to substrates and effector 
functions.
SIRT3 is the main mitochondrial deacetylase4, 5. SIRT3 concentrates primarily to the matrix of the mitochon-
dria but may also localize into the nucleus6, 7. SIRT3 deacetylase activity is intrinsically linked to cell metabolism8. 
SIRT3 promotes fatty acid β-oxidation, tricarboxylic acid cycle, ketogenesis, urea cycle and brown adipose tissue 
thermogenesis9–15. SIRT3 also regulates the activity of the electron transport chain and dampens oxidative stress 
by targeting superoxide dismutase 2 and the glutathione system16. As a regulator of metabolism and oxidative 
stress homeostasis, SIRT3 protects from aging and age-associated dysfunctions, and genetic studies identified 
SIRT3 polymorphisms associated with increased longevity17–20.
SIRT3 protects from stress-induced cardiovascular diseases and impacts on the development of neurodegen-
erative and oncologic diseases21–28. SIRT3 deficiency increases allograft graft injury, diabetic cardiac dysfunction, 
insulin resistance, acute kidney injury and lung fibrosis29–38, suggesting that SIRT3 may counteract the develop-
ment of chronic metabolic and inflammation-related disorders. SIRT3 has been reported to drive oncogenic and 
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tumor-suppressive effects39. All these observations stimulated the development of both activators and inhibitors 
of SIRT3 for clinical purposes40. Within this context, it is important to ascertain that SIRT3 targeting would not 
negatively impact on host resistance to infection, an aspect of SIRT3 biology that is so far poorly characterized41, 42.
In the present study, we used SIRT3 knockout mice to investigate whether SIRT3 deficiency altered the 
response of immune cells to microbial ligands in vitro. We then analyzed the impact of SIRT3 deficiency in a panel 
of severe and non-severe models of endotoxemia, peritonitis, pneumonia, listeriosis and candidiasis. Overall, our 
results suggest that SIRT3 deficiency has no major impact on host defenses against infections, supporting the 
safety of SIRT3-oriented therapies currently under development.
Materials and Methods
Ethics statement. Animal experimentations were approved by the Service de la Consommation et des 
Affaires Vétérinaires (SCAV) du Canton de Vaud (Epalinges, Switzerland) under authorizations n° 876.8, 
and 877.8, and performed according to Swiss guidelines and ARRIVE guidelines (http://www.nc3rs.org.uk/
arrive-guidelines).
Mice, cells and reagents. Sirt3 floxed (Sirt3L2/L2) mice were generated as described43 and crossed with 
mice expressing the CMV-Cre deleter in the male germline to create full knockouts. SIRT3−/− mice were back-
crossed nine times on a C57BL6/J background. Mice were housed under specific pathogen-free conditions and 
were exempt of mouse hepatitis virus and murine norovirus infections. Splenocytes were cultured in RPMI 1640 
medium containing 2 mM glutamine, 50 μM 2-ME, 100 IU/ml penicillin, 100 μg/ml streptomycin (Invitrogen, 
San Diego, CA) and 10% heat-inactivated fetal calf serum (FCS, Sigma-Aldrich St. Louis, MO)44. Bone marrow 
(BM) cells were cultured seven days in IMDM (Invitrogen) containing 2-ME, penicillin, streptomycin, 10% FCS 
and 50 U/ml macrophage colony-stimulating factor or 250 U/ml granulocyte macrophage colony-stimulating 
factor (Immunotools, Friesoythe, Germany) to generate BM-derived macrophages (BMDMs) and dendritic cells 
(BMDCs)45. For experiments, 105, 5 × 105 or 2 × 106 cells were seeded in 96, 24 or 6-well plates in complete 
medium without growth factor and antibiotics. The stimuli used were: Salmonella minnesota ultra pure LPS 
(List Biologicals Laboratories, Campbell, CA), Pam3CSK4 (EMC microcollections, Tübingen, Germany), CpG 
ODN 1826 (CpG, InvivoGen, San Diego, CA), concanavalin A (Sigma-Aldrich), anti-CD3ε and CD28 antibodies 
(clones 145-2C11 and 37.51, eBioscience, San Diego, CA) and toxic shock syndrome toxin-1 (TSST-1, Toxin 
Technology, Sarasota, FL). Clinical strains of Escherichia coli O18 (E. coli), Klebsiella pneumoniae caroli (K. pneu-
moniae), Group B Streptococcus (GBS)46–49 and Listeria monocytogenes 10403 s (L. monocytogenes, a gift from 
D. Zehn, Lausanne University Hospital, Switzerland) were grown in brain heart infusion broth (BD Biosciences, 
Erembodegem, Belgium). Candida albicans 5102 (C. albicans)44 was cultured in yeast extract-peptone-dextrose 
(BD Biosciences). Bacteria were heat-inactivated for in vitro experiments50.
RNA analyses. RNA was isolated and reverse transcribed using the RNeasy and QuantiTect reverse tran-
scription kits (Qiagen, Hilden, Germany). Real-time PCR was conducted using the Fast SYBR® Green Master 
Mix and a QuantStudio™ 12 K Flex system (Life Technologies, Carlsbad, CA)44, 45. Primers have been described45, 51. Sirt3 expression was normalized to actin expression. Sirt3 mRNA expression levels in organs were extracted 
from the BioGPS resource (http://biogps.org).
Western blot analyses. Proteins were extracted from liver or BMDMs using RIPA lysis buffer (150 mM 
NaCl, 50 mM Tris-HCl pH 7.4, 1 mM EDTA, 1% Triton-X-100, 0.1% NP-40, 1 mM PMSF) or an in house cell lysis 
buffer (150 mM NaCl, 10 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.5% NP-40, 1 mM PMSF, 1 mM Na-orthovanadate, 
10 mM NaF) containing protease and phosphatase inhibitors (Merck)52, 53 and electrophoresed through 
SDS-PAGE54. Membranes were incubated with antibodies directed against SIRT3 and total and phosphorylated 
ERK1/2, p38 and JNK (Cell Signaling Technology), then with a secondary horseradish peroxidase-conjugated 
antibody (Sigma-Aldrich). Blots were revealed with the enhanced chemiluminescence Western blotting system 
(GE Healthcare, Little Chalfont, Royaume-Uni). Images were recorded using a Fusion Fx system (Viber Lourmat, 
Collégien, France).
Flow cytometry. Single cell suspensions from thymus and spleen were incubated with 2.4G2 monoclo-
nal antibody (mAb) and stained using mAbs listed in Supplementary Table S1 as described previously55. Data 
were acquired using a LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo Version 8.5.3 software 
(FlowJo LLC, Ashland OR).
Proliferation assay. Splenocytes were cultured in 96-well plates for 48 hours with different stimuli and pro-
liferation quantified by measuring 3H-thymidine incorporation over 18 hours56.
Cytokine measurements. Cytokines were quantified using DuoSet ELISA kits (R&D Systems, Abingdon, 
UK)57.
In vivo models. Eight to twelve-week-old SIRT3+/+ and SIRT3−/− C57BL/6 J mice matched for age were used. 
Endotoxemia was performed by challenging mice intraperitoneally (i.p.) with 400 μg LPS (20 mg/kg). Peritonitis, 
pneumonia, listeriosis and candidiasis were induced by injecting i.p. 1–3 × 104 CFU E. coli, intranasally (i.n.) 30 
CFU K. pneumoniae, intravenously (i.v.) 105 CFU L. monocytogenes and i.v. 105, 3 × 105 or 106 CFU C. albicans, 
respectively. Blood, spleen and liver were collected 1–48 hours post-challenge to quantify cytokines and bacteria. 
Survival and severity scores graded from 1 to 5 were registered at least once daily58. Animals were euthanized 
when they met a severity score of 4. Animal follow-up was performed by two operators.
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Statistical analyses. Comparisons between groups were performed using the ANOVA F-test followed by 
two-tailed unpaired Student’s t-test. Survival curves were built using the Kaplan-Meier method and differences 
were analyzed by the log-rank sum test. All analyses were performed using PRISM (GraphPad, San Diego, CA). P 
values were two-sided and significance level was set at 0.05.
Results
SIRT3 deficiency has no major impact on the composition of thymic and splenic immune cell 
subsets and on the response of splenocytes to immune stimuli. SIRT3 is expressed ubiquitously, 
including in immune organs (Fig. 1A). SIRT3−/− mice used in this study were backcrossed nine times on a 
C57BL6/J background. SIRT3−/− mice developed without macroscopic abnormalities and expressed no detecta-
ble levels of SIRT3 protein (Fig. 1B). The absolute number of cells and the proportions of the major immune cell 
subsets in the thymus and the spleen were similar in SIRT3+/+ and SIRT3−/− mice, including CD4/CD8 double 
negative (DN1-4), double positive (DP) and single positive (SP) thymocytes and splenic CD3+ T cells (DN and 
SP, naïve and memory), B220+ B cells (immature and mature) and CD11c+ DCs (Table 1 and Table 2). SIRT3+/+ 
and SIRT3−/− splenocytes were cultured for 48 hours with LPS (TLR4 ligand), Pam3CSK4 (TLR1/TLR2 ligand), 
CpG (TLR9 ligand), concanavalin A, anti-CD3/CD28 and TSST-1 before measuring cell proliferation and IL-2 
and IFNγ production. SIRT3+/+ and SIRT3−/− splenocytes reacted similarly to all stimuli (Fig. 1C and D). Hence, 
SIRT3 deficiency had no apparent impact on immune cell development and splenocyte response to stimulation.
SIRT3 deficiency does not alter macrophage and dendritic cell response to microbial prod-
ucts. TLR triggering activates the MAPK pathway involved in the control of cytokine production1. To test 
whether SIRT3 had an impact on the response of macrophages to TLR ligands, the phosphorylation of ERK1/2, 
p38 and JNK MAPKs in BMDMs exposed for 0, 10, 30 and 60 minutes to LPS was analyzed by Western blotting 
(Fig. 2A). ERK1/2, p38 and JNK phosphorylation was reduced in SIRT3−/− BMDMs 10 minutes post-stimulation 
(Fig. 2A). No differences were observed 30 and 60 minutes post-stimulation. Nonetheless, SIRT3+/+ and 
Figure 1. SIRT3 deficiency does not influence proliferation and cytokine response of splenocytes. (A) Sirt3 
mRNA expression levels in a panel of organs (from the BioGPS resource). A.U.: arbitrary units. (B) SIRT3 
protein expression in SIRT3+/+ and SIRT3−/− liver (protein extracts from lanes 1 and 3 and lanes 2 and 4 were 
obtained using RIPA lysis buffer and in house cell lysis buffer, respectively) assessed by Western blotting. Full-
length blots are presented in Supplementary Figure S1. The first lane of each blot corresponds to a molecular 
weight marker. (C,D) SIRT3+/+ and SIRT3−/− splenocytes were incubated for 48 hours with LPS (5 µg/ml), 
Pam3CSK4 (10 µg/ml), CpG (2 µg/ml), concanavalin A (5 µg/ml), anti-CD3/CD28 antibodies (1 µg/ml) and 
TSST-1 (2 µg/ml). (C) Proliferation was measured by 3H-thymidine incorporation. Data are means ± SD of 
triplicate samples from one experiment performed with 3 mice and are representative of 2 experiments. (D) 
IL-2 and IFNγ concentrations in cell culture supernatants were quantified by ELISA. Data are means ± SD from 
two experiments each performed with 3 mice.
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 3853  | DOI:10.1038/s41598-017-04263-x
SIRT3−/− BMDMs secreted comparable levels of TNF and IL-6 (t = 8 hours) in response to stimulation with LPS, 
Pam3CSK4, CpG, E. coli and GBS (Fig. 2B). SIRT3+/+ and SIRT3−/− BMDCs also produced identical levels of TNF 
and IL-6 when exposed to the same panel of stimuli (Fig. 2C). In agreement with these observations, SIRT3+/+ 
and SIRT3−/− BMDMs expressed similar mRNA levels of a selection of PRRs (Tlr1, Tlr2, Tlr6, Tlr9, Cd14, 
Md2, Msr1) and cytokines/chemokines (Il1a, Il1b, Il10, Il12b, Il15, Il27, Ccl2/Mcp1, Ccl3/Mip1a, Ccl4/Mip1b, 
Cxcl1/Groa, Cxcl10/Ip10, Cxcl11/Itac) at baseline and 2 hours following stimulation with LPS (Supplementary 
Figure S3). Altogether, these results suggested that SIRT3 deficiency marginally influenced MAPK signaling and 
cytokine production by macrophages and DCs exposed to TLR ligands and whole bacteria.
SIRT3 deficiency does not affect the course of endotoxemia and bacterial and fungal infec-
tions. To address the relevance of our in vitro findings, we developed a model of endotoxemia by challenging 
mice i.p. with 20 mg/kg LPS (Fig. 3A and B). TNF and IL-12p40 concentrations in blood collected from SIRT3+/+ 
and SIRT3−/− mice 1 hour (TNF) and 6 hours (IL-6) post-challenge were comparable (Fig. 3A). In line with these 
results, the overall survival of SIRT3+/+ and SIRT3−/− mice was similar (75% vs 89%, P = 0.4, Fig. 3B).
We next examined the contribution of SIRT3 to host defenses against bacterial pneumonia and peritoni-
tis, listeriosis and candidiasis. Infection models of diverse severity were used considering that SIRT3-mediated 
hypo-inflammatory response would jeopardize survival to otherwise non-lethal infection, while SIRT3-mediated 
hyper-inflammatory response would worsen outcome during severe infection47, 51. SIRT3+/+ and SIRT3−/− mice 
survived equivalently to non-severe pneumonia induced by K. pneumoniae (82.5% vs 93%, P = 0.4, Fig. 3C). 
In a model of fulminant E. coli peritonitis, where all deaths occurred within 3 days, bacterial loads in blood 
collected 18 hours post-infection (median: 4.7 × 106 CFU/ml vs 5.2 × 106 CFU/ml; P = 0.4) and survival (27% vs 
27%) were identical in SIRT3+/+ and SIRT3−/− mice (Fig. 3D and E). Listeriosis was induced by i.v. challenge with 
the intracellular bacterium L. monocytogenes. Two days post-infection, bacteremia was low but slightly higher 
SIRT3+/+ SIRT3−/−
CD4+ CD8+ 82.3 ± 3.1 84.3 ± 1.0
CD4− CD8− 2.0 ± 0.6 1.6 ± 0.1
 CD25− CD44+ 1.4 ± 0.6 1.2 ± 0.2
 CD25+ CD44+ 0.1 ± 0.01 0.1 ± 0.03
 CD25+ CD44− 1.8 ± 0.6 1.8 ± 0.3
 CD25− CD44− 96.6 ± 1.2 96.8 ± 0.42
CD4+ CD8− 12.0 ± 2.3 10.6 ± 0.7
CD4− CD8+ 3.6 ± 0.3 3.5 ± 0.2
Table 1. Thymic cell subsets in SIRT3+/+ and SIRT3−/− mice. Data are means ± SD of 4 animals per group 
and expressed as the percentage of total cells (CD4+ CD8+, CD4− CD8−, CD4+ CD8− and CD4− CD8+) or 
percentage of CD4− CD8− parental cells (CD25− CD44+, CD25+ CD44+, CD25+ CD44− and CD25− CD44−). 
Total cell numbers were 49.2 ± 15.4 and 47.4 ± 6.9 millions per thymus in SIRT3+/+ and SIRT3−/− mice, 
respectively. No statistically significant differences in subsets’ percentages and absolute numbers were detected.
SIRT3+/+ SIRT3−/−
CD3+ T cells (%) 27.3 ± 4.6 31.1 ± 1.0
  CD4+ 62.3 ± 2.7 61.2 ± 4.2
  CD4+ CD44low CD62Lhigh (naive) 46.0 ± 4.2 48.9 ± 6.8
  CD4+ CD44high CD62Llow (memory) 16.2 ± 2.6 12.0 ± 2.8
  CD8+ 31.5 ± 2.0 32.5 ± 3.3
   CD8+ CD44low CD62Lhigh (naive) 23.3 ± 1.0 28.6 ± 1.7
  CD8+ CD44high CD62Llow (memory) 8.2 ± 0.5 6.6 ± 0.3
  CD4− CD8− 1.3 ± 0.1 1.5 ± 0.3
B220+ B cells (%) 50.5 ± 7.6 53.3 ± 3.1
  B220+ IgD+ CD23+ (mature) 45.7 ± 2.6 48.8 ± 2.7
  B220+, non-IgD+/CD23+ (immature) 6.5 ± 0.5 6.4 ± 0.5
CD11c+ DCs (%) 6.2 ± 0.5 6.5 ± 0.6
  B220− 62.8 ± 2.5 59.4 ± 2.6
  B220+ 37.2 ± 2.5 40.6 ± 2.6
Table 2. Splenic cell subsets in SIRT3+/+ and SIRT3−/− mice. Data are means ± SD of 4 animals per group and 
expressed as the percentage of CD3+, B220+, and CD11c+ splenic cells or the percentage of the CD3+, B220+ 
and CD11c+ parental populations expressing CD4, CD8, CD44, CD62L, IgD and CD23. Total cell numbers 
were 75.1 ± 7.5 and 75.4 ± 21.1 millions per spleen in SIRT3+/+ and SIRT3−/− mice, respectively. No statistically 
significant differences in subset’s percentages and absolute numbers were detected.
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in SIRT3−/− mice (median: 7.5 × 102 CFU/ml vs 1.1 × 103 CFU/ml; P = 0.02). L. monocytogenes burden in spleen 
and liver was massive but not significantly different between SIRT3+/+ and SIRT3−/− mice (3.6 × 106 CFU/mg vs 
4.9 × 106 CFU/mg, P = 0.8 and 1.3 × 105 CFU/mg vs 1.8 × 105 CFU/mg, P = 0.1; Fig. 4A). Death occurred between 
days 2 and 7, and overall survival was not influenced by SIRT3 deficiency (0% vs 7%, P = 0.5, Fig. 4B). Finally, 
candidiasis was induced by inoculating 105, 3 × 105 or 106 CFU C. albicans to produce a mild/chronic infection 
inducing animal death over a period of 5 weeks or a severe infection leading to animal death within 3 days. In the 
three models, the survival rates of SIRT3+/+ and SIRT3−/− mice were comparable (90% vs 70%, P = 0.3; 56% vs 
56%, P = 0.8 and 0% vs 0%, P = 0.8) (Fig. 5A–C).
Discussion
We report that SIRT3 deficiency has no major impact on immune cell development and host defenses against 
bacterial and fungal infections. These observations are particularly topical considering the promises of 
SIRT3-targeting strategies to treat age-related disorders.
SIRT3 deficiency did not alter the composition of the main lymphoid and DC subsets in thymus and spleen, 
in line with a previous study showing normal thymic, splenic and lymph node CD4+ and CD8+ T-cell sub-
populations in SIRT3−/− mice, including CD4+ Foxp3+ T regulatory cells (Tregs)29. Immune cells exposed to 
microbial products or cytokines undergo metabolic reprogramming characterized by a switch from oxidative 
Figure 2. SIRT3 does not affect TNF and IL-6 production by BMDMs and BMDCs exposed to microbial 
stimuli. SIRT3+/+ and SIRT3−/− BMDMs (A,B) and BMDCs (C) were exposed to LPS (10 ng/ml), Pam3CSK4 
(10 ng/ml), CpG (2 µg/ml), E. coli (106 CFU/ml) and GBS (2.5 × 106 CFU/ml). (A) Expression levels of 
phosphorylated (p) and total ERK1/2, JNK and p38 were analyzed by Western blotting and quantified by 
imaging. Data are means ± SD obtained with 3 mice. Full-length blots are presented in Supplementary 
Figure S2. (B,C) TNF and IL-6 concentrations in cell culture supernatants collected 8 hours after stimulation. 
Data are means ± SD of triplicate samples from one experiment performed with 3 mice and are representative of 
2 experiments.
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Figure 3. SIRT3 deficiency does not affect the course of endotoxemia and bacterial infection. SIRT3+/+ and 
SIRT3−/− mice were injected i.p. with 400 μg LPS ((A,B) n = 8–9 per group), i.n. with 30 CFU K. pneumoniae 
((C) n = 17 SIRT3+/+ and 14 SIRT3−/− mice) and i.p. with 1–3 × 104 CFU E. coli ((D,E) n = 11 per group). (A) 
TNF and IL-6 concentrations in blood collected 1 hour (TNF) and 6 hours (IL-6) after LPS challenge. P = 0.1 
and 0.2. (B,C and E) Survival of mice. P = 0.4, 0.4 and 1.0 (D) CFU counts in blood collected 18 hours after E. 
coli challenge. P = 0.4.
Figure 4. SIRT3 deficiency does not impact on organ colonization and survival of mice infected with L. 
monocytogenes. SIRT3+/+ and SIRT3−/− mice (A) n = 14–15 per group; (B) n = 14–16 per group) were injected 
i.v. with 105 CFU L. monocytogenes. ((A) Blood, spleen and liver were collected 48 hours after challenge to 
quantify bacterial loads. P = 0.02, 0.8 and 0.1. (B) Survival of mice. P = 0.5.
Figure 5. SIRT3 deficiency does not impact on survival of mice infected with C. albicans. SIRT3+/+ and 
SIRT3−/− mice were injected i.v. with 105 (A) n = 10 per group), 3 × 105 (B) n = 9 per group) and 106 CFU C. 
albicans (C) n = 12 per group). (A–C) Survival of mice. P = 0.3, 0.8 and 0.5.
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phosphorylation to glycolysis associated with the development of inflammatory and antimicrobial functions59. 
Considering that SIRT3 impacts on mitochondrial biogenesis and functions60, we expected SIRT3 deficiency to 
enhance immune cell response to microbial stimulation. MAPK phosphorylation was reduced to some extend 
early on after LPS stimulation in SIRT3−/− BMDMs. However, proliferation and cytokine production by spleno-
cytes, macrophages and DCs were largely unaffected by SIRT3 deficiency. In contrast, shRNA-mediated SIRT3 
silencing increased baseline TNF mRNA levels in RAW 264.7 macrophages61, and adenovirus-mediated SIRT3 
overexpression inhibited MAPK phosphorylation in phenylephrine-treated myocytes and palmitate-stimulated 
pancreatic beta-cells62, 63. Thus, SIRT3 seems to have cell and possibly context-dependent effects. Supporting 
this assumption, SIRT3 deficiency impaired in vitro the suppressive function of Tregs, which are particularly 
dependent on SIRT3-mediated mitochondrial activity and oxidative phosphorylation to develop optimal func-
tions. However, SIRT3−/− Tregs retained their suppressive functions in an adoptive transfer model of cardiac 
allograft rejection29. SIRT3 deficiency also affected endothelial function in mice fed with a high cholesterol diet 
but not a normal diet64, and organ-specific SIRT3 deficiency increased mitochondrial protein acetylation but 
did not induce mitochondrial dysfunction and did not impact on overall metabolic homeostasis as observed in 
germline SIRT3 knockouts43, 65.
To assess the safety of SIRT3-targeting therapies, it was most important to analyze the contribution of SIRT3 
in preclinical models of infection. As a first approach, we tested a model of endotoxemia, which revealed that 
cytokine response and survival rates were not different in SIRT3+/+ and SIRT3−/− mice. Although SIRT3−/− mice 
survived slightly better than SIRT3+/+ mice, whether this was a genuine effect would require large groups of ani-
mals (>40 mice per genotype) according to power calculation. Albeit very unlikely, we also cannot totally rule out 
that some differences in the genetic background of SIRT3+/+ and SIRT3−/− mice play a role. To address that ques-
tion, SIRT3−/− mice with additional backcrosses should be tested. SIRT3+/+ mice had a minor yet significant sur-
vival advantage (10% vs 0% survival in SIRT3+/+ vs SIRT3−/− mice) in a highly stringent model of endotoxemia38, 
suggesting that SIRT3 may provide benefits in sterile, deep inflammatory, processes. Unfortunately, the cytokine 
response was not reported. Endotoxemia does not recapitulate the complexity to host defense mechanisms gener-
ated to fight against living microorganisms. Moreover, immunomodulatory compounds may interfere with innate 
immune responses and compromise host defenses, as well documented for anti-TNF and anti-IL-1 agents66, 67. 
Thus, we elected to test models of sepsis induced by E. coli and K. pneumoniae, two of the most frequent etiologic 
agents of human sepsis. SIRT3 deficiency did not impact on the development of sub-acute pneumoniae and acute 
peritonitis, going well along with normal in vitro responses to bacterial stimulation of immune cells. In line with 
our observations, the survival rates of SIRT3+/+ and SIRT3−/− mice were not significantly different following cecal 
ligation and puncture sepsis22. Additionally, SIRT3+/+ and SIRT3−/− mice behaved roughly identically following 
systemic infection with L. monocytogenes and C. albicans given to produce chronic/mild and acute candidiasis. 
Interestingly, Listeria loads were slightly increased in the blood of SIRT3−/− mice, which might feature transient 
alteration of mitochondrial dynamics during L. monocytogenes infection68. However, bacteremia was very low 
when compared to liver and spleen bacterial burdens, which were not different between SIRT3+/+ and SIRT3−/− 
mice. The absence of patent phenotype in a panel of sepsis models suggests that infection-induced phagocyte 
recruitment and/or activity was not impaired in SIRT3−/− mice. Indeed, SIRT3 deficiency did not affect endothe-
lial activation, plaque macrophage and T cell infiltration and atherosclerosis in low-density lipoprotein receptor 
knockout mice64. Our observations are somehow reminiscent of that obtained analyzing SIRT1. While SIRT1 was 
globally shown to inhibit inflammation69, it had little impact on macrophage and neutrophil antimicrobial func-
tions, and myeloid deficiency in SIRT1 did not influence the outcome of endotoxemia and Gram-positive sepsis70.
SIRT3 activity is strongly associated with metabolism, and there is a tight relationship between metabolism 
and immune functions59. Thus, work will be required to address whether SIRT3 impacts on host defenses under 
metabolic stress. It is also possible that sirtuins have complementary or redundant effects, as suggested by pro-
tein interaction studies5. Therefore, future studies should analyze the impact of targeting multiple sirtuins on 
innate immune responses. Supporting this strategy, dual inhibitors of SIRT1/2 and pan-classical HDAC inhibitors 
affected host defenses against infections46, 51, 56, 71. Considering that SIRT3 has been associated with age-related 
dysfunctions and that immune functions are decreased in elderly72, one should analyze the impact of SIRT3 in 
populations of different ages. Finally, a limitation of this study is that preclinical mouse models were performed 
with female mice. In a preliminary experiment using a limited number of males (seven animals), the survival 
of SIRT3+/+ and SIRT3−/− mice to Klebsiella-induced pneumonia was not different. However, larger groups of 
mice and additional models should be tested to settle whether there is or not a sex-dependent impact of SIRT3 
deficiency on susceptibility to infection.
Overall, our data support the assumption that SIRT3 has no major impact on innate immune functions and 
host defenses against bacterial and fungal infections, at least in healthy immunocompetent hosts. The present 
data largely support the safety of SIRT3-oriented therapies, in terms of susceptibility to infections, for treating 
metabolic, oncologic and neurodegenerative diseases.
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